• Publications
  • Influence
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
BACKGROUND Secukinumab is an anti-interleukin-17A monoclonal antibody that has been shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted two phase 3 trials ofExpand
  • 505
  • 24
  • PDF
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
BACKGROUND We assessed the efficacy and safety of brodalumab, a human monoclonal antibody against interleukin-17 receptor A (IL17RA), in a phase 2, randomized, double-blind, placebo-controlled studyExpand
  • 293
  • 10
  • PDF
OP0218 Efficacy and safety results of guselkumab, an anti-il23 monoclonal antibody, in patients with active psoriatic arthritis over 24 weeks: a phase 2a, randomized, double-blind, placebo-controlled
Objectives To evaluate the efficacy, safety, and tolerability of guselkumab (GUS), a fully human monoclonal antibody against the p19 subunit of IL-23, in patients (pts) with active psoriaticExpand
  • 25
  • 2
Extremity magnetic resonance imaging in rheumatoid arthritis: Updated literature review
Introduction In April 2006, a white paper on extremity magnetic resonance imaging (MRI) in rheumatoid arthritis (RA) was published, based on a review of the literature by a task force commissioned byExpand
  • 15
Comparison of three methods for calculating the Bath Ankylosing Spondylitis Metrology Index in a randomized placebo‐controlled study
To compare 3 methods for calculating the Bath Ankylosing Spondylitis Metrology Index (BASMI) score using patients who participated in the GO‐RAISE study.
  • 17
OP0113 No Increased Incidence of Inflammatory Bowel Disease among Secukinumab-Treated Patients with Moderate To Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2
Background Secukinumab (SEC), a fully human anti–interleukin-17A monoclonal antibody, has been evaluated and approved for the treatment of moderate to severe psoriasis (PsO), active psoriaticExpand
  • 12
Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study
Introduction‘REASSURE’ (NCT01377012), a phase 3 study, evaluated the efficacy and safety of secukinumab in patients with active rheumatoid arthritis (RA) who had an inadequate response to, orExpand
  • 15
  • PDF
SAT0270 Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis
Background Uveitis, a common extra-articular manifestation of SpA, has an estimated prevalence in patients (pts) with ankylosing spondylitis (AS) of 33.2%, which increases with disease duration andExpand
  • 6
Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study
To report the primary (1‐year) results from PREVENT, the first phase III study evaluating secukinumab in patients with active nonradiographic axial spondyloarthritis (SpA).
  • 6
AB0753 COMPARING COMPOSITE MEASURES OF DISEASE ACTIVITY IN PSORIATIC ARTHRITIS: RESULTS FROM A RANDOMIZED PHASE 2 TRIAL WITH GUSELKUMAB
Background: Psoriatic arthritiS Disease activity Score (PASDAS), GRAppa Composite scorE (GRACE) index, modified Composite Psoriatic Disease activity index (mCPDAI), and Disease activity index forExpand
  • 1